alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of the Treasury

###### Office of Thrift Supervision

Notice is hereby given that, pursuant to the authority contained in section 5(d)(2) of the Home Owners' Loan Act, the Office of Thrift Supervision (OTS) has duly appointed the Federal Deposit Insurance Corporation as sole Receiver for La Jolla Bank, FSB, La Jolla, California (OTS No. 08247), on February 19, 2010.

Dated: February 22, 2010.

By the Office of Thrift Supervision.

Sandra E. Evans,

Federal Register Liaison.

[FR Doc. 2010-4038 Filed 3-2-10; 8:45 am]

BILLING CODE 6720-01-M
<TABLE> <S> <C>



<ARTICLE>                                           7
<MULTIPLIER>                                   1,000,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   DEC-31-2000
<DEBT-HELD-FOR-SALE>                           18,761
<DEBT-CARRYING-VALUE>                          0
<DEBT-MARKET-VALUE>                            0
<EQUITIES>                                     718
<MORTGAGE>                                     0
<REAL-ESTATE>                                  0
<TOTAL-INVEST>                                 21,191
<CASH>                                         196
<RECOVER-REINSURE>                             6,436
<DEFERRED-ACQUISITION>                         1,494
<TOTAL-ASSETS>                                 38,564
<POLICY-LOSSES>                                22,475
<UNEARNED-PREMIUMS>                            2,584
<POLICY-OTHER>                                 0
<POLICY-HOLDER-FUNDS>                          2,062
<NOTES-PAYABLE>                                1,654
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    150
<COMMON>                                       5
<OTHER-SE>                                     5,870
<TOTAL-LIABILITY-AND-EQUITY>                   38,564
<PREMIUMS>                                     8,001
<INVESTMENT-INCOME>                            1,315
<INVESTMENT-GAINS>                             522
<OTHER-INCOME>                                 293
<BENEFITS>                                     6,727
<UNDERWRITING-AMORTIZATION>                    1,913
<UNDERWRITING-OTHER>                           798
<INCOME-PRETAX>                                605
<INCOME-TAX>                                   24
<INCOME-CONTINUING>                            581
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   581
<EPS-BASIC>                                    0
<EPS-DILUTED>                                  0
<RESERVE-OPEN>                                 13,210
<PROVISION-CURRENT>                            4,401
<PROVISION-PRIOR>                              934
<PAYMENTS-CURRENT>                             1,290
<PAYMENTS-PRIOR>                               4,811
<RESERVE-CLOSE>                                12,202
<CUMULATIVE-DEFICIENCY>                        1,207



</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
THE COMPANY'S CONSOLIDATED FINANCIAL STATEMENTS OF INCOME AND
CONSOLIDATED BALANCE SHEETS AND IS QUALIFIED BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-END>                               DEC-28-1996
<CASH>                                            9310
<SECURITIES>                                      9318
<RECEIVABLES>                                    66230
<ALLOWANCES>                                      5129
<INVENTORY>                                      85924
<CURRENT-ASSETS>                                 18981
<PP&E>                                            9440
<DEPRECIATION>                                    5457
<TOTAL-ASSETS>                                  187526
<CURRENT-LIABILITIES>                           130557
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             6
<OTHER-SE>                                       56969
<TOTAL-LIABILITY-AND-EQUITY>                    187526
<SALES>                                         298701
<TOTAL-REVENUES>                                298701
<CGS>                                           268878
<TOTAL-COSTS>                                   268878
<OTHER-EXPENSES>                                 21254
<LOSS-PROVISION>                                   843
<INTEREST-EXPENSE>                                   4
<INCOME-PRETAX>                                   4544
<INCOME-TAX>                                      1678
<INCOME-CONTINUING>                               2866
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      2866
<EPS-PRIMARY>                                      .50
<EPS-DILUTED>                                      .50
        

</TABLE>
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 12-6531

COREY JAWAN ROBINSON,

Plaintiff - Appellant,

v.

SOUTH CAROLINA DEPARTMENT OF CORRECTIONS; JON OZMINT; JAMES 

BLACKWELL; SGT. W. YOUNG; TIFFANY STARKS; SARAH M. ROBERTS; 

ANN HALLMAN; HCA GREGORY SARVER; LIEBER CORRECTIONAL 

INSTITUTION; DAVID TATARSKY; ANNA MOAKS; CANDACE A. WIGFALL; 

RAMNARINE JAGLAL; LT. DESSIRENCE LLOYD; SGT. Y. BLOWE; DHO 

A. BROWN; WARDEN WAYNE MCCAVE; CPL. GREALIN FRAIZER; SGT. J. 

SMITH; DOCTOR R. BABB,

Defendants - Appellees.

Appeal from the United States District Court for the District of 

South Carolina, at Orangeburg. Henry M. Herlong, Jr., Senior

District Judge. (5:10-cv-02593-HMH)

Submitted: July 26, 2012 Decided: August 2, 2012

Before MOTZ, DAVIS, and FLOYD, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Corey Jawan Robinson, Appellant Pro Se. Elloree Ann Ganes, 

Robert Holmes Hood, Jr., Thomas Happel Scurry, HOOD LAW FIRM, 

Charleston, South Carolina, for Appellees.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Corey Jawan Robinson appeals the district court’s 

order accepting the recommendation of the magistrate judge and 

denying relief on his 42 U.S.C. § 1983 (2006) complaint. We 

have reviewed the record and find no reversible error. 

Accordingly, we affirm for the reasons stated by the district 

court. Robinson v. S.C. Dep’t of Corr., No. 5:10-cv-02593-HMH 

(D.S.C. Mar. 13, 2012). We dispense with oral argument because

the facts and legal contentions are adequately presented in the 

materials before the court and argument would not aid the 

decisional process.

AFFIRMED
I 

118TH CONGRESS 

1ST SESSION H. R. 769 

To designate the National Museum of the Mighty Eighth Air Force in 

Pooler, Georgia, as the official National Museum of the Mighty Eighth 

Air Force in the United States, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 2, 2023 

Mr. CARTER of Georgia (for himself, Mr. CRENSHAW, Mr. WITTMAN, Mr. 

CLYDE, Mr. JOHNSON of Ohio, and Mr. AUSTIN SCOTT of Georgia) introduced the following bill; which was referred to the Committee on Armed 

Services 

A BILL 

To designate the National Museum of the Mighty Eighth 

Air Force in Pooler, Georgia, as the official National 

Museum of the Mighty Eighth Air Force in the United 

States, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. NATIONAL MUSEUM OF THE MIGHTY EIGHTH 

4 AIR FORCE. 

5 (a) DESIGNATION.—The National Museum of the 

6 Mighty Eighth Air Force located at 175 Bourne Avenue, 

7 Pooler, Georgia (or any successor location), is designated 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 769 IH

1 as the official National Museum of the Mighty Eighth Air 

2 Force of the United States (referred to in this section as 

3 the ‘‘National Museum’’). 

4 (b) RELATION TO NATIONAL PARK SYSTEM.—The 

5 National Museum shall not be included as a unit of the 

6 National Park System. 

7 (c) RULE OF CONSTRUCTION.—This section shall not 

8 be construed to appropriate, or authorize the appropria9 tion of, Federal funds for any purpose related to the Na10 tional Museum. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
# C_2014431EN.01002402.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/24 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/24

---

Order of the President of the General Court of 4 September 2014 — Energiewerke Nord v Commission

(Case T-288/14 R)

((Application for interim measures - State aid - National support for the generation of renewable electricity - Commission decision to open the State aid formal investigation procedure - Application for suspension of operation of a measure - Prima facie case))

(2014/C 431/42)

Language of the case: German

Parties

Parties

Applicant: Energiewerke Nord GmbH (Rubenow, Germany) (represented by: T. Volz and B. Wißmann, lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian Rusche and R. Sauer, Agents)

Defendant:

Re:

Re:

Application to suspend the legal effects of the decision by which the Commission opened the State aid formal investigation procedure concerning the German law on renewable energy.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The costs are reserved. |
| --- | --- |

2.

The costs are reserved.

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5765 Retinol-binding protein immunological test system. ( a ) *Identification.* A retinol-binding protein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the retinol-binding protein that binds and transports vitamin A in serum and urine. Measurement of this protein may aid in the diagnosis of kidney disease and in monitoring patients with kidney transplants.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2313, Jan. 14, 2000]
Certification by the Chief Executive Officer Pursuant to Section 302


EX-31.1


Exhibit 31.1  RULE 13a-14(a)/15d-14(a) CERTIFICATION  I, David F. Levy, President, certify that:  1. I have reviewed this quarterly report on Form 10-QSB of InZon Corporation .  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;  4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [omitted pursuant to extended compliance period] for the small business issuer and have:  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;  (b)  [omitted pursuant to extended compliance period]  (c) Evaluated the effectiveness of the small business issuers disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and  (d) Disclosed in this report any change in the small business issuers internal control over financial reporting that occurred during the small business issuers most recent fiscal quarter (the small business issuers fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuers internal control over financial reporting; and  5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuers auditors and the audit committee of the small business issuers board of directors (or persons performing the equivalent functions):  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuers ability to record, process, summarize and report financial information; and  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuers internal control over financial reporting.
 Dated: August 21, 2006By: /s/ David F. LevyDavid F. LevyPresident, Principal Executive Officer
Exhibit 10.2


 


[BANK OF THE WEST LETTERHEAD]


 


 


May 9, 2017


 


 


CONDITIONAL WAIVER LETTER


 


 


H.D.D. LLC


125 Foss Creek Circle


Healdsburg, CA 95448


Attention: Phillip L. Hurst


 


		Re:	Loan and Security Agreement dated July 6, 2015 (the “Agreement”) executed by H.D.D. LLC (the “Borrower”)
and Bank of the West, a California banking corporation (the “Lender”).



 


Dear Mr. Hurst:


 


The Lender has become aware of certain breach of the terms of
the Agreement, which constitute an Event of Default thereunder. The breach is described as follows (references are to section of
the Agreement):


 


4.21(d) EBITDA to Current Portion of Long-Term
Debt plus Interest Expense. Borrower failed to maintain a ratio of (1) EBITDA plus contributions minus unfinanced capital expenditures
minus dividends, withdrawals and distributions to (2) Current Portion of Long-Term Debt plus Interest Expense, of not less than
1.25 to 1.0, measured at the end of each fiscal quarter for fiscal quarter ending 3/31/2017.


 


Except to the extent of this and any prior waiver, the Agreement
shall remain unaltered and in full force and effect. This letter shall not be a waiver of any existing Event of Default or breach
of a covenant unless specified herein, whether now existing or hereafter occurring and whether now known or hereafter discovered.


 


This waiver shall be effective only upon receipt by the Bank
of the enclosed acknowledgment copy executed by the Borrowers along with your payment for the waiver fee in the amount of $5,000.00.
If the foregoing is acceptable, please sign the enclosed copy and return, along with your payment, for the amount due to the undersigned
not later than May 23, 2017.


 


Sincerely,


 


 


Bank of the West,


a California banking corporation


 


 


 


	By: 	/s/ Marina Kremer	 
	 	Marina Kremer, Vice President	 




 




     


     


    

 


 


ACCEPTANCE


 


 


Borrower accepts the terms and conditions
of this Conditional Waiver Letter and agrees to be bound thereby. Borrower acknowledges that this acceptance constitutes Borrower’s
representation and warranty that Borrower has made no loans or extensions of credit to any person during the current fiscal year.


 


Accepted and Agreed to this    9    day
of May, 2017


 


 


Borrower:


 


H.D.D. LLC


 


	By:	Truett-Hurst, Inc., Manager


 


 


	 	By: 	/s/ Phillip L. Hurst	 
	 	 	Phillip L. Hurst, Chief Executive Officer/Chairman
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1345 Intravascular bleed monitor. ( a ) *Identification.* An intravascular bleed monitor is a probe, catheter, or catheter introducer that measures changes in bioimpedance and uses an algorithm to detect or monitor progression of potential internal bleeding complications.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) In vivo animal performance testing must demonstrate that the device performs as intended under anticipated conditions of use and evaluate the following: ( i ) Device performance characteristics;
( ii ) Adverse effects, including gross necropsy and histopathology; and
( iii ) Device usability, including device preparation, device handling, and user interface.
( 2 ) Non-clinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Tensile testing of joints and materials;
( ii ) Mechanical integrity testing;
( iii ) Friction testing;
( iv ) Flush testing;
( v ) Air leakage and liquid leakage testing;
( vi ) Latching and unlatching testing;
( vii ) Kink and bend testing;
( viii ) Insertion force testing;
( ix ) Torque testing;
( x ) Corrosion testing; and
( xi ) Dimensional tolerance testing.
( 3 ) Performance data must support the sterility and pyrogenicity of the device components intended to be provided sterile.
( 4 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 5 ) The patient contacting components of the device must be demonstrated to be biocompatible.
( 6 ) Software verification, validation, and hazard analysis must be performed.
( 7 ) Performance data must demonstrate electromagnetic compatibility (EMC), electrical safety, thermal safety, and mechanical safety.
( 8 ) Human factors performance evaluation must demonstrate that the user can correctly use the device, based solely on reading the directions for use.
( 9 ) Labeling must include: ( i ) Instructions for use;
( ii ) A shelf life and storage conditions;
( iii ) Compatible procedures;
( iv ) A sizing table; and
( v ) Quantification of blood detected.
[87 FR 34778, June 8, 2022]
#### Bernice Friedson *v.*Zoning Board of Appeals of the Town of Westport et al.

*Joseph F. McKeon, Jr.,*for the appellee (named defendant).

Argued December 3

decided December 3, 1968

The motion by the defendants to dismiss the appeal from the Court of Common Pleas in Fairfield County is granted.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1825 Vitamin D test system. ( a ) *Identification.* A vitamin D test system is a device intended for use in clinical laboratories for the quantitative determination of 25-hydroxyvitamin D (25-OH-D) and other hydroxylated metabolites of vitamin D in serum or plasma to be used in the assessment of vitamin D sufficiency.
( b ) *Classification.* Class II (special controls). Vitamin D test systems must comply with the following special controls: ( 1 ) Labeling in conformance with 21 CFR 809.10 and
( 2 ) Compliance with existing standards of the National Committee on Clinical Laboratory Standards.
[63 FR 40366, July 29, 1998]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7741 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7741

To direct the President to oppose any waiver of obligations of members 
 of the World Trade Organization under the Agreement on Trade-Related 
  Aspects of Intellectual Property Rights unless a statute is enacted 
                  expressly authorizing such a waiver.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 20, 2024

    Mr. Burchett (for himself, Mr. Fleischmann, Mr. Guest, and Mr. 
 Rutherford) introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To direct the President to oppose any waiver of obligations of members 
 of the World Trade Organization under the Agreement on Trade-Related 
  Aspects of Intellectual Property Rights unless a statute is enacted 
                  expressly authorizing such a waiver.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Trade Related Intellectual Property 
Protection Act'' or the ``TRIPP Act''.

SEC. 2. OPPOSITION TO WAIVER OF OBLIGATIONS OF WTO MEMBERS UNDER THE 
              TRIPS AGREEMENT.

    The President shall oppose any waiver of obligations of members of 
the World Trade Organization under the TRIPS Agreement unless a statute 
is enacted expressly authorizing such a waiver.

SEC. 3. TRIPS AGREEMENT DEFINED.

    In this Act, the term ``TRIPS Agreement'' means the Agreement on 
Trade-Related Aspects of Intellectual Property Rights referred to in 
section 101(d)(15) of the Uruguay Round Agreements Act (19 U.S.C. 
3511(d)(15)).
                                 <all>
```